Floatz logo

zg19018

KRAS G12C Mutant Advanced Solid Tumors

Suzhou Zelgen Biopharmaceuticals Co.,LtdPhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the KRAS G12C Mutant Advanced Solid Tumors cohort.

Asset / SponsorPhaseRating
Cetuximab
Zhejiang University
Phase 2CCC
Fulzerasib
Zhejiang University
Phase 2CCC

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →